Multicenter Randomized Parallel Group Phase III Study Comparing the Bowel Cleansing Efficacy, Safety and Tolerability of NER1006 Versus MOVIPREP® Using 2-Day Split-Dosing and 1-Day Morning Split-Dosing Regimen in Adults.

NCT02273167 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

849

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Colorectal Carcinoma
Colon Cleansing

Interventions

DRUG: NER1006, 2-Day Split-Dosing
DRUG: NER1006,1-Day Morning Split-Dosing
DRUG: MOVIPREP, 2-Day Split-Dosing

Sponsor

Norgine